Mycobacterial disease attributable to tumor necrosis factor-α blockers

Clinical Infectious Diseases

Volumn 47, Issue 12, 2008, Pages 1603-1605

  Wallis, Robert S ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DETERIORATION; DRUG EFFICACY; HUMAN; INFECTION RISK; LETTER; MORTALITY; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; MYCOBACTERIUM INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56749150561     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/593366     Document Type: Letter

References (21)

1. Iseman MD, Fischer A. Tumor necrosis factor-α at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin Infect Dis 2008; 46:1741-2.
2. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738-40.
3. Wallis RS, Broder MS, Wong JY, Beenhouwer DO. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39:1254-5.
4. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43:717-22.
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372-9.
6. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76.
7. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986-92.
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-12.
9. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1436-9.
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122-7.
11. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
12. Fonseca JE, Canhão H, Silva C. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience [in Portuguese]. Acta Reumatol Port 2006; 31:247-53.
13. Tubach F, Salmon-Ceron D, Ravaud P, Mariette X. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapy. Joint Bone Spine 2005; 72:456-60.
14. Salmon D, Tubach F, Ravaud P. A risk of tuberculosis persists in patients treated with anti TNF-a antagonist therapy despite prophylactic guidelines: identification of main risk factors [abstract O471]. In: Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases (Munich, Germany). 2007.
15. Wallis RS. Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8:601-11.
16. Enbrel prescribing information. Thousand Oaks, CA, and Madison, NJ: Amgen and Wyeth Pharmaceuticals, 2007. Available at: http://www.enbrel.com/ prescribing-information.jsp. Accessed 8 August 2008.
17. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58:947-52.
18. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195:1643-50.
19. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004; 1:CD003574.
20. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-94.
21. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-85.